Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of iparomlimab + tuvonralimab as first-line treatment for MSI-H/dMMR or POLE/POLD1-mutated metastatic colorectal cancer
ChiCTR2500103181Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of iparomlimab and tuvonralimab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 cohorts), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2500103181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103181.